LITSLITSHealthcare · Biotechnology

LITS Stock Forecast: Lite Strategy, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$1.00
+5.99% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 28 of 100 as at 22 Aug 2026 — in the lower half.

Market cap
$36.0M
Ticker Nerd rank
28 / 100
Median analyst target
Analysts covering
Total return, dividends reinvested
1W
+12.3%
1M
−0.0%
YTD
−24.3%
1Y
−78.4%
From 52W high
−81.1%
From 52W low
+35.1%
$0.74
$5.28
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

LITS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Lite Strategy, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
28 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
86
Size
85
Volatility
70
Accruals
48
Quality
48
Issuance
25
Revisions
25
Value
18
Momentum
3

Growth (86): Sales and profits are climbing, and climbing faster than before.

Momentum (3): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

LITS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LITS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00$5.00Oct 25Jan 26Apr 26Jul 26LITS

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LITS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

LITS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Lite Strategy, Inc. (LITS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.4×

Cheaper than 79% of US stocks

Price / sales
Price / book
0.6×

Cheaper than 83% of US stocks

EV / EBITDA
−1.5×

Cheaper than 69% of US stocks

Growth & margins
Revenue growth (YoY)
Earnings growth (YoY)
Gross margin
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−159.3%

Higher than 9% of US stocks

Return on assets
−27.7%

Higher than 15% of US stocks

Dividend yield

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

LITS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
LITSLite Strategy, Inc.$36.0M
28
BCTXBriaCell Therapeutics Corp.$35.1M
7
ATNMActinium Pharmaceuticals, Inc.$34.5M
69
NNVCNanoViricides, Inc.$33.8M
58
QNCXQuince Therapeutics, Inc.$33.2M
25
IGCIGC Pharma, Inc.$31.8M
6
CRVOCervoMed, Inc.$39.6M
29

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Lite Strategy, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LITS news & analysis

Lite Strategy Repurchases 13% of Outstanding Shares Since December, Increasing Litecoin Backing Per Share

GlobeNewsWire · 30 July 2026positive

Lite Strategy repurchased approximately 4.9 million shares, or 13% of its outstanding shares, under its Share Repurchase Program between December 2025 and July 17, 2026, deploying about $5.4 million at an average price of $1.11 per share through treasury operations.

Why it matters — A LITS watcher would care because the buyback reduces the total share count, increasing the amount of Litecoin backing each remaining share.

FAQ

Frequently asked questions about LITS stock

How does Ticker Nerd's model rank LITS?

As at 22 Aug 2026, Lite Strategy, Inc. ranks 28 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (86 of 100).

What is the LITS stock forecast for 2030?

No analyst covering Lite Strategy, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LITS are extrapolating price history, which says nothing about the business.

How has LITS stock performed over the past year?

Lite Strategy, Inc. returned -78.4% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Lite Strategy, Inc. do?

Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer.

What is the latest news on LITS?

The most recent item we track (GlobeNewsWire, 30 July 2026): "Lite Strategy Repurchases 13% of Outstanding Shares Since December, Increasing Litecoin Backing Per Share". Lite Strategy repurchased approximately 4.9 million shares, or 13% of its outstanding shares, under its Share Repurchase Program between December 2025 and July 17, 2026, deploying about $5.4 million at an average price of $1.11 per share through treasury operations.

Company

About Lite Strategy, Inc.

Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.

CEO Mr. Justin J. File CPA · 4 employees · United States · https://www.litestrategy.com